Página principal   |  Sobre esta colección  |  Ayuda  |  Aclarar       Inglés  |  Francés  |  Español  
Documento completo
Capítulo completo
Expandir índice
Preferencias
Ir a la sección anterior Ir a la siguiente sección

cerrar este libroGuidelines for the Treatment of Malaria (WHO; 2006; 266 pages) Ver el documento en el formato PDF
Ver el documentoGlossary
Ver el documentoAbbreviations
abrir esta carpeta y ver su contenido1. Introduction
Ver el documento2. The clinical disease
abrir esta carpeta y ver su contenido3. Treatment objectives
abrir esta carpeta y ver su contenido4. Diagnosis of malaria
abrir esta carpeta y ver su contenido5. Resistance to antimalarial medicines9
cerrar esta carpeta6. Antimalarial treatment policy
Ver el documento6.1 Assessment of in vivo therapeutic efficacy
Ver el documento6.2 Criteria for antimalarial treatment policy change
abrir esta carpeta y ver su contenido7. Treatment of uncomplicated P. Falciparum malaria10
abrir esta carpeta y ver su contenido8. Treatment of severe falciparum malaria14
abrir esta carpeta y ver su contenido9. Treatment of malaria caused by P. vivax, P. ovale or P. malariae19
Ver el documento10. Mixed malaria infections
abrir esta carpeta y ver su contenido11. Complex emergencies and epidemics
abrir esta carpeta y ver su contenidoAnnexes
 

6.2 Criteria for antimalarial treatment policy change

These malaria treatment guidelines recommend that antimalarial treatment policy should be changed at treatment failure rates considerably lower than those recommended previously. This major change reflects the availability of highly effective drugs, and the recognition both of the consequences of drug resistance, in terms of morbidity and mortality, and the importance of high cure rates in malaria control.

It is now recommended that a change of first-line treatment should be initiated if the total failure proportion exceeds 10%. However, it is acknowledged that a decision to change may be influenced by a number of additional factors, including the prevalence and geographical distribution of reported treatment failures, health service provider and/or patient dissatisfaction with the treatment, the political and economical context, and the availability of affordable alternatives to the commonly used treatment.

Summary of recommendations on changing antimalarial treatment policy

RECOMMENDATIONS

LEVEL OF EVIDENCE

In therapeutic efficacy assessments, the cure rate should be defined parasitologically, based on a minimum of 28 days of follow-up. Molecular genotyping using PCR technology should be used to distinguish recrudescent parasites from newly acquired infections.

E

Review and change of the antimalarial treatment policy should be initiated when the cure rate with the current recommended medicine falls below 90% (as assessed through monitoring of therapeutic efficacy).

E

A new recommended antimalarial medicine adopted as policy should have an average cure rate ≥95% as assessed in clinical trials.

E

 

Ir a la sección anterior Ir a la siguiente sección

Por favor envíe sus comentarios   Inglés  |  Francés  |  Español